SEPSIS & COVID-19 SYMPOSIUM

A virtual meeting on September 28-29, 2020

Sepsis & COVID-19 Symposium Keynote Speakers

Derek C. Angus, MD, MPH, FRCP University of Pittsburgh



Dr. Derek Angus is the Chief Healthcare Innovation Officer for UPMC and the Associate Vice Chancellor for Healthcare Innovation at the University of Pittsburgh Schools of the Health Sciences. He is a physician scientist and healthcare administrator, his specialty training is in critical care medicine, he holds the rank of Distinguished Professor, and he is the Mitchell P. Fink Endowed Chair in Critical Care Medicine at the University of Pittsburgh. He also chairs the Department of Critical Care Medicine at the University of Pittsburgh and at UPMC. Dr. Angus' research interests include translational, clinical, and health services research in the fields of sepsis, pneumonia, and multisystem organ failure, as well as optimal acute care delivery. He has a particular interest in novel trial designs for precision medicine, causal inference, and strategies to enable a true rapid learning health system. Dr. Angus has led multiple large NIH-funded multicenter studies, published several hundred papers, is a Clarivate Highly Cited Researcher, and has received numerous national and international awards for his work. He is also a senior editor for JAMA.

Mark D. Williams, MD, FCCM, FCCP Indiana University School of Medicine



Mark D. Williams graduated with a B.S. in Biology and a MD both from Indiana University. He completed a residency at Wake Forest University, Winston-Salem, NC and a fellowship in pulmonary critical care at Indiana University. Currently, Dr. Williams holds a Clinical Associate Professor of Pulmonary Critical Care Medicine at Indiana University. He has had multiple corporate appointments including at Eli Lilly and Company, BioCritica, Inc., Astute Medical and is the CEO of Bench to Bedside Consulting, LLC.

Timothy G. Buchman, MD, PhD Emory University



Timothy G. Buchman has four decades of bedside experience caring for septic patients. A general surgeon, intensive care doctor and virologist, he is currently Senior Advisor, IPA to the Division of Research, Innovation, and Ventures (DRIVe), Biomedical Advanced Research and Development Authority (BARDA), Office of Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (HHS). Dr. Buchman's other current roles include Professor of Surgery, Anesthesiology, and Biomedical Informatics at Emory University, where he founded the Emory Critical Care. Dr. Buchman is past president of the Shock Society, of the Society for Complex Acute Illness and of the Society of Critical Care Medicine, the latter being the largest organization of critical care professionals in the world . He is Editor-in-Chief of *Critical Care* **Medicine** and **Critical Care Explorations** .He is also a member of the External Faculty of the Santa Fe Institute. He also serves as site director of the military-civilian partnership, Surgical Critical Care Institute. Dr. Buchman's current research focuses on the use of artificial intelligence to predict which patients in the intensive care unit will become septic.

Anne Louise Kjølbye, MSc, PhD, MBA Livag, Vedbaek, Denmark



Anne Louise Kjølbye received her MSc and PhD from the University of Copenhagen. Dr. Kjølbye completed an Executive MBA in Management of Technology at the Swiss Federal Institute of Technology, Lausanne. Dr. Kjølbye has twenty years' experience in Biotech and Pharma of which 15 have been in leadership positions. She has experience in all parts of the value chain from early idea generation to Phase 3 trials. The past 10 years Dr. Kjølbye has been "in the machine room" of developing new drugs for sepsis. At Ferring, she led the selepressin program for septic shock and pioneered the use and regulatory acceptability of a novel composite endpoint to be used for the first time in a pivotal trial. Also, Dr. Kjølbye fully embraced the novel possibilities of adaptive trial design and incorporated several novel features such as response adaptive randomization into the selepressin Phase 2b/3 pivotal trial, something that was not seen before in a registration trial in sepsis. Last year Dr. Kjølbye founded her own consultancy company and she is now using her experience from drug development in critical care together with her excellent analytical skills and ability to integrate scientific, medical and business needs into effective development strategies and executable plans to support biotech companies within the field of critical care and other indications. As such Dr Kjølbye is well positioned to talk about "What pharma needs to see to try again with sepsis?

Organizing Committee

Rashid Bashir, PhD University of Illinois at Urbana-Champaign



Ephraim Tsalik, MD, PhD Duke University School of Medicine



Matthew Churpek, MD, MPH University of Wisconsin, Madison



Karen White, MD, PhD Carle Foundation Hospital



Gregory Martin, MD, MSc Emory University



Leon Yeh, MD OSF St. Francis Medical Center



Bobby Reddy, Jr., PhD University of Illinois at Urbana-Champaign



Panel Speakers



Gordon Bernard

MD

Vanderbilt University,
Department of
Medicine



Sarah Dunsmore **PhD** *National Institute of General Medical Sciences (NIGMS)*



Tim Blauwkamp **PhD** *Karius*



Reena Duseja MD, MS Centers for Medicare & Medicaid Services (CMS)



Denise Cardo
MD
Centers for Disease
Control and Prevention
(CDC)



E. Wesley Ely MD, MPH Vanderbilt University School of Medicine VA TN Valley GRECC



Matthew Churpek
MD, MPH
University of Wisconsin,
Madison



Aldo Faisal **PhD** *Imperial College, London*



Gari Clifford **PhD** *Emory University*



Victor Jeger
MD, PhD
University of Zurich,
Switzerland



Ivor Douglas
MD, FRCP (UK)
University of Colorado,
School of Medicine



Vincent X. Liu
MD, MSc
Kaiser Permanente



Gregory Martin MD, MSc Emory University



Kristian Roth

PhD

Food & Drug

Administration (FDA) /

CDRH



Keith McCrea
PhD
ExThera Medical



Kimberly Sciaretta **PhD** Biomedical Advanced Research & Development Authority (BARDA)



Nuala Meyer MD, MS (MSTR) Cincinnati Children's Hospital Medical Center



Christopher Seymour MD, MSc University of Pittsburgh, School of Medicine



David Persing MD, PhD Cepheid



Tim Sweeney MD, PhD Inflammatix, Inc.



Hallie Prescott MD, MSc University of Michigan; VA Ann Arbor Healthcare System



Hector Wong MD Cincinnati Children's Hospital Medical Center



Chanu Rhee
MD, MPH
Harvard University
Population
Medicine

Disclosures

Not available Derek Angus, MD, MPH FRCP Rashid Bashir, PhD Prenosis Inc.; Helios Gordon Bernard, MD Cumberland Pharm; Eli Lilly; DSMB (Bayer) Tim Blauwkamp, PhD Karius Tim Buchman, MD PhD Amgen (spouse) Denise Cardo, MD Nothing to disclose Matthew Churpek, MD MPH University of Chicago; EarlySense Gari Clifford, PhD Nothing to disclose Ivor Douglas, MD FRCP (UK) Nothing to disclose Sarah Dunsmore, PhD Nothing to disclose Reena Duseja, MD MS Nothing to disclose NIH/VA Kohler; Pfizer Orion; Masimo E. Wesley Ely, MD MPH Aldo Faisal, PhD Nothing to disclose Victor Jeger, MD PhD Roche Diagnostics International Ltd. Anne Louise Kjølbye, MSc PhD MBA Nothing to disclose King Li, MD MBA Nothing to disclose Vincent Liu, MD MSc The Permanente Medical Group Greg Martin, MD MSc Grifols; Genentech Keith McCrea, PhD ExThera Medical Nuala Meyer, MD MS (MSTR) Nothing to disclose **David Persing**, MD PhD Nothing to disclose Nothing to disclose Hallie Prescott, MD MSc Bobby Reddy, Jr., PhD Prenosis Inc. Chanu Rhee, MD MPH Nothing to disclose Kristian Roth, PhD Nothing to disclose Nothing to disclose Kimberly Sciarretta, PhD Christopher Seymour, MD MSc Nothing to disclose Tim Sweeney, MD PhD Inflammatix Inc.

Predigen Inc.

LaJolla Pharma

Nothing to disclose

Ephraim Tsalik, MD PhD

Hector Wong, MD

Mark Williams, MD FCCM FCCP

Thank you to our Co-Hosts and Sponsors







Dean King Li, MD, MBA



Dean Rashid Bashir, PhD